Log in
Enquire now
‌

US Patent 10071140 Amylin analogues

Patent 10071140 was granted and assigned to Zealand Pharma A/S on September, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Zealand Pharma A/S
Zealand Pharma A/S
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10071140
Date of Patent
September 11, 2018
Patent Application Number
15698743
Date Filed
September 8, 2017
Patent Citations Received
‌
US Patent 12115210 Long acting amylin receptor agonists and uses thereof
0
‌
US Patent 11382956 Amylin analogues
‌
US Patent 12018059 Human amylin analog polypeptides and methods of use
0
‌
US Patent 12083164 Amylin analogues
0
‌
US Patent 10766939 Amylin analogues
Patent Primary Examiner
‌
Jeanette M Lieb
Patent abstract

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10071140 Amylin analogues

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.